You are here: Industry Insights > 2024

News List

Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
New FDA Regulations in the Year 2024 Muhammad Asim Niazi
January 07, 2025
The United States FDA regulates pharma drug products manufactured or marketed in the United States. There are many different functions of the FDA, and one of them is devising new regulations.
Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024 PharmaSources
August 26, 2024
Avantor, Inc. has secured three prestigious awards at the esteemed Korea Biopharma Excellence Awards (KBEA) 2024.
InnoCare Releases 2024 Interim Results and Business Highlights August 21, 2024
InnoCare Pharma announced the 2024 interim results and corporate update as of 30 June 2024.
Popular Products and Companies at PharmaSources.com (June 2024) PharmaSources
June 25, 2024
Popular Products and Companies at PharmaSources.com
Pharma Sources Insight June 2024: Globalization on the GO! Pharma Sources Insight
June 29, 2024
Pharma Sources Insight JUNE 2024 focuses on wearable delivery system, sythetic biology, pharmaceutical globalization and more.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress PharmaSources
June 14, 2024
Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress PharmaSources
June 05, 2024
Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
Vetter Wins Best Managed Companies Award 2024 PharmaSources
May 30, 2024
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win.